‌

US Patent 10828259 Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor

Patent 10828259 was granted and assigned to Pharmacyclics on November, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 10, 2020

Patent Application Number

16846064

Date Filed

April 10, 2020

Patent Citations

US Patent 10266540 Crystalline forms of a Bruton's tyrosine kinase inhibitor

US Patent 10294232 Crystalline forms of a Bruton's tyrosine kinase inhibitor

US Patent 10294231 Crystalline forms of a Bruton's tyrosine kinase inhibitor

US Patent 10010507 Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

US Patent 10065968 Crystalline forms of a bruton's tyrosine kinase inhibitor

US Patent 10106548 Crystalline forms of a Bruton's tyrosine kinase inhibitor

US Patent 10125140 Crystalline forms of a bruton's tyrosine kinase inhibitor

US Patent 10213386 Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor

Patent Citations Received

US Patent 10961251 Crystalline forms of a Bruton's tyrosine kinase inhibitor

Patent Primary Examiner

Jeffrey H Murray

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10828259 Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.